Sopharma Trading AD (XBUL:SFT) 3-Year EBITDA Growth Rate : 17.00% (As of Sep. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Sopharma Trading AD 3-Year EBITDA Growth Rate?

Sopharma Trading AD's EBITDA per Share for the three months ended in Sep. 2023 was лв0.47.

During the past 12 months, Sopharma Trading AD's average EBITDA Per Share Growth Rate was -8.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 17.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 20.50% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sopharma Trading AD was 25.30% per year. The lowest was 2.20% per year. And the median was 16.60% per year.

Competitive Comparison of Sopharma Trading AD's 3-Year EBITDA Growth Rate

For the Medical Distribution subindustry, Sopharma Trading AD's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sopharma Trading AD's 3-Year EBITDA Growth Rate Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sopharma Trading AD's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sopharma Trading AD's 3-Year EBITDA Growth Rate falls into.

Sopharma Trading AD 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sopharma Trading AD (XBUL:SFT) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Sopharma Trading AD 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sopharma Trading AD's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sopharma Trading AD (XBUL:SFT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sopharma Trading AD (XBUL:SFT) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sunrise Street, Lachezar Stanchev, 5 Sopharma, Business Towers, Building A Floor 12, Sofia, BGR, 1756

Website

http://www.sopharmatrading.bg

Sopharma Trading AD is a Bulgaria based company operating in the pharmaceutical sector. The company is engaged in the distribution of pharmaceutical items, including a portfolio of international brands, medicinal products, medical supplies, sanitary and hygienic materials, vitamins, nutritional supplements, cosmetics, medical equipment, and equipment. It also provides turnkey solutions for the construction of medical and hospital establishments. In addition, the group also caters logistics solutions for import, storage, and distribution of goods to end customers.

Sopharma Trading AD (XBUL:SFT) Headlines

No Headlines